

Disclosures

Personal Commercial (42)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Akros	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
American Regent	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Amgen	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Amgen Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Boston Scientific	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bristol-Myers Squibb Company	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Cytokinetics	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Fast Biomedical	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Gilead Sciences	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Gilead Sciences, Inc.	Other - Scientific Grant Review Board	Modest (< \$5,000)	General Cardiology
GlaxoSmithKline	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
HeartWare	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Janssen	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Luitpold Pharmaceuticals, Inc	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Luitpold Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Medtronic	Research/Research Grants ‡ Optivol in LVAD patients	None (\$0)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novartis Corporation	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Otsuka Pharmaceutical Co.	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Pharmacosmos	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pharmacosmos	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
ResMed	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Respicardia	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Rocket	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sanofi-Aventis	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Thoratec	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Vifor	Other - <i>Trial leadership role</i>	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Vifor	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Windtree	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/7/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 6/7/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 6/7/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 6/7/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.